logologo
QuantliQuantli

Anika Therapeutics Inc

ANIK

NASDAQ

Biotechnology

$21.50

USD

+0.33 (+1.56%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $286.13M

Volume 124.9K

Price (USD)
Price (USD)

About Anika Therapeutics Inc

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 235 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

CEO

Mr. Stephen Griffin

HQ

Bedford, MASSACHUSETTS, US

Founded

1985

Employees

235

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

6 metrics our research team weighs before forming a view on ANIK.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Revenue Growth (TTM)

5.3%

+25.9 pp

Gross Margin (TTM)

62.2%

+4.9 pp

Operating Margin (TTM)

-4.2%

+3.8 pp

Net Margin (TTM)

-3.1%

+49.8 pp

ROE (TTM)

-2.8%

+38.3 pp

Free Cash Flow (TTM)

$562,000

Financial Snapshot

Full Financials

Revenue

$120.65M

+5.3%

YoY

Gross Margin

62%

TTM

+8.6%

YoY

Net Income

$-3.78M

+93.8%

YoY

Operating Cash Flow

$5.98M

-4.8%

YoY

Key Statistics

Open

$21.17

Previous Close

$21.17

Day Range

$21.04 - $21.98

52 Week Range

$8.22 - $22.88

Volume

124.9K

Average Volume (10 Days)

150.0K

Dividend Yield

Valuation Measurement

Market Cap

$286.13M

P/E Ratio (TTM)

P/S Ratio (TTM)

2.37

Price / Book

2.08

Financial Highlights

Profit Margin

-3.1%

Return on Assets

-2.1%

Return on Equity

-2.8%

Revenue (TTM)

$120.65M

Net Income (TTM)

$-3.78M

Diluted EPS (TTM)

-$0.27

Total Cash (MRQ)

$38.41M

Levered FCF (TTM)

$562,000

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Go deeper on ANIK

Similar Stocks

SION

Sionna Therapeutics Inc

$6.46

-1.2%

AVXL

Anavex Life Sciences Corp

$3.22

-1.5%

FATE

Fate Therapeutics Inc

$2.57

+2.0%

IRD

Opus Genetics Inc

$3.61

-3.0%

SRZN

Surrozen Inc

$23.96

+1.0%

MYGN

Myriad Genetics Inc

$3.03

-4.4%

TRDA

Entrada Therapeutics Inc

$7.46

+0.1%

ALXO

ALX Oncology Holdings Inc

$1.96

+1.0%

ZSQR

Z Squared Inc (Delaware)

$3.94

-5.3%

ELDN

Eledon Pharmaceuticals Inc

$3.54

-4.3%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 03

Est. EPS

Adjusted consensus estimate

$0.05